Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.94 EUR
Change Today -0.025 / -2.60%
Volume 424.4K
TIG On Other Exchanges
As of 11:35 AM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

tigenix nv (TIG) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/1/15 - €1.31
52 Week Low
10/16/14 - €0.48
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TIGENIX NV (TIG)

Related News

No related news articles were found.

tigenix nv (TIG) Related Businessweek News

No Related Businessweek News Found

tigenix nv (TIG) Details

TiGenix NV, a biopharmaceutical company, develops and commercializes cell therapy products. Its pipeline is based on a validated platform of allogeneic expanded adipose-derived stem cells (eASC) targeting autoimmune and inflammatory diseases. The company is developing Cx601, which is in Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn’s disease; Cx611, an allogeneic eASC that has completed Phase IIb clinical trial for the treatment of rheumatoid arthritis and Phase Ib trail for severe sepsis; and Cx621, which has completed a Phase I trial for the treatment of intra lymphatic administration of allogeneic eASCs. It has operations in Belgium, the Netherlands, Spain, and internationally. TiGenix NV was founded in 2000 and is headquartered in Leuven, Belgium.

49 Employees
Last Reported Date: 03/27/15
Founded in 2000

tigenix nv (TIG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: €476.6K
Compensation as of Fiscal Year 2014.

tigenix nv (TIG) Key Developments

TiGenix N.V. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-08-2015 01:15 PM

TiGenix N.V. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-08-2015 01:15 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Claudia Jiménez, Senior Director Business Development.

TiGenix N.V. Announces Consolidated Earnings Results for the Six-Month of 2015

TiGenix N.V. announced consolidated earnings results for the six-month of 2015. For the six months, the company reported total revenues increased by 14% to EUR 0.9 million compared to EUR 0.8 million in the same period of 2014, mainly driven by royalties and other operating income received from Sobi. Operating loss amounted to EUR 9.6 million compared to EUR 7.1 million during the same period of 2014. This increase is attributable to a higher spend on research and development activities. The net financial loss amounted to EUR 1.1 million compared to EUR 0.2 million during the same period of 2014. Loss was EUR 10.6 million, compared to EUR 9.2 million for the same period in 2014, representing an increase of 15%.

TiGenix N.V., H1 2015 Earnings Call, Sep 15, 2015

TiGenix N.V., H1 2015 Earnings Call, Sep 15, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TIG:BB €0.94 EUR -0.025

TIG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Vericel Corp $2.55 USD +0.06
View Industry Companies

Industry Analysis


Industry Average

Valuation TIG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.1x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIGENIX NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at